cyclohexyl 2-oxopyridine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: cyclohexyl 2-oxopyridine-1-carboxylate
• 英文别名: Cyclohexyl-2-oxopyridine 1-carboxylate
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: BMUBROQJYHHZQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  D-苏氨酸 、 碳酸氢钠 、 、 、 cyclohexyl 2-oxopyridine-1-carboxylate 在 crude mixture 、 乙醚 、 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 水 、 四氢呋喃 为溶剂， 反应 15.0h， 以to afford the title compound (0.3 g, 97%) as transparent oil, which的产率得到(2R,3S)-2-(((cyclohexyloxy)carbonyl)amino)-3-hydroxybutanoic acid
  参考文献：
  名称：

  Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

  摘要：

  本发明提供了抑制N-酰基乙醇胺酸酰胺酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在浓度降低的情况下的棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物。本发明还提供了治疗炎症性疾病和疼痛，以及其他与PEA和OEA浓度降低相关的疾病的方法。

  公开号：

  US09353075B2
• 作为产物：
  描述：

  碳酸二(2-吡啶)酯 、 环己醇 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 生成 cyclohexyl 2-pyridyl carbonate 、 cyclohexyl 2-oxopyridine-1-carboxylate
  参考文献：
  名称：

  Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

  摘要：

  本发明提供了用于抑制N-酰基乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的紊乱的方法。

  公开号：

  US09353075B2

文献信息

• [EN] DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)<br/>[FR] BÊTA-LACTONES DISUBSTITUÉS EN TANT QU'INHIBITEURS DE L'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA)
  申请人：UNIV CALIFORNIA

  公开号：WO2013078430A1

  公开（公告）日：2013-05-30

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和药物组合物。考虑到抑制NAAA是一种维持棕榈酰乙醇胺（PEA）和油酰乙醇胺（OEA）水平的方法，这两种物质是NAAA的底物，在特征为PEA和OEA浓度降低的情况下。该发明还提供了治疗炎症性疾病和疼痛以及其他与降低PEA和OEA水平相关的疾病的方法。
• A Convenient Method for the Preparations of Carboxamides and Peptides by Using Di(2-pyridyl) Carbonate and<b><i>O</i></b>,<b><i>O</i></b>^′-Di(2-pyridyl) Thiocarbonate as Dehydrating Reagents
  作者：Isamu Shiina、Yoshihito Suenaga、Masakazu Nakano、Teruaki Mukaiyama

  DOI：10.1246/bcsj.73.2811

  日期：2000.12

  di(2-pyridyl) carbonate (DPC) or O,O′-di(2-pyridyl) thiocarbonate (DPTC) in the presence of a catalytic amount of 4-(dimethylamino)pyridine (DMAP). The formation of 2-pyridyl esters, key intermediates of the reaction, from carboxylic acids by using DPC proceeded faster than by using DPTC; therefore, the former carbonate is more efficiently employed in the above condensation reactions.

  通过使用二（2-吡啶基）碳酸酯（DPC）或O，O'-二（2-吡啶基）硫代碳酸酯（DPTC）在存在下进行脱水缩合，从游离羧酸和胺中以高产率制备羧酰胺和肽催化量的 4-（二甲氨基）吡啶 (DMAP)。与使用 DPTC 相比，使用 DPC 由羧酸形成 2-吡啶基酯（反应的关键中间体）的速度更快；因此，在上述缩合反应中更有效地使用前一种碳酸酯。
• Disubstituted Beta-lactones as Inhibitors of N-Acylethanolamine Acid Amidase (NAAA)
  申请人：The Regents of the University of California

  公开号：US20130281490A1

  公开（公告）日：2013-10-24

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了一种抑制N-酰乙醇胺酸酰胺酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在低浓度下的PEA和OEA的水平的方法，这两种物质是NAAA的底物。本发明还提供了治疗炎症性疾病、疼痛和其他与PEA和OEA浓度降低相关的疾病的方法。
• DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)
  申请人：Fondazione Istituto Italiano Di Tecnologia

  公开号：US20160235707A1

  公开（公告）日：2016-08-18

  The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

  本发明提供了用于抑制N-乙酰基乙醇胺酸酰化酶（NAAA）的化合物和制药组合物。抑制NAAA被认为是一种维持在PEA和OEA两种NAAA底物的水平在浓度降低的情况下的方法。本发明还提供了用于治疗炎症性疾病和疼痛以及其他与PEA和OEA水平下降相关的疾病的方法。
• Synthesis, Biological Evaluation, and 3D QSAR Study of 2-Methyl-4-oxo-3-oxetanylcarbamic Acid Esters as <i>N</i>-Acylethanolamine Acid Amidase (NAAA) Inhibitors
  作者：Stefano Ponzano、Anna Berteotti、Rita Petracca、Romina Vitale、Luisa Mengatto、Tiziano Bandiera、Andrea Cavalli、Daniele Piomelli、Fabio Bertozzi、Giovanni Bottegoni

  DOI：10.1021/jm501455s

  日期：2014.12.11

  N-(2-Oxo-3-oxetanyl)carbamic acid esters have recently been reported to be noncompetitive inhibitors of the N-acylethanolamine acid amidase (NAAA) potentially useful for the treatment of pain and inflammation. In the present study, we further explored the structure-activity relationships of the carbamic acid ester side chain of 2-methyl-4-oxo-3-oxetanylcarbamic acid ester derivatives. Additional favorable features in the design of potent NAAA inhibitors have been found together with the identification of a single digit nanomolar inhibitor. In addition, we devised a 3D QSAR using the atomic property field method. The model turned out to be able to account for the structural variability and was prospectively validated by designing, synthesizing, and testing novel inhibitors. The fairly good agreement between predictions and experimental potency values points to this 3D QSAR model as the first example of quantitative structure-activity relationships in the field of NAAA inhibitors.